• Efrat Harel, Jun Shoji, Vivek Abraham, Loan Miller, Zoltan Laszik, Tine Thurison, Andrew King, Adam Olshen, Joey Leung, Gyula Szabo, Byron Hann, Gunilla Høyer-Hansen, Charles S Craik, and Flavio Vincenti.
• Department of Pharmaceutical Chemistry, University of California, San Francisco, California.
• Clin Transplant. 2019 Mar 1; 33 (3): e13487.

BackgroundWe investigated circulating levels of individual soluble urokinase plasminogen activation receptor (suPAR) forms to determine if specific circulating fragments of suPAR (II-III) and (I) can better serve as clinical biomarkers for focal segmental glomerulosclerosis (FSGS) and the risk of recurrence after transplantation.Materials And MethodsSerum levels of intact suPAR and its cleaved forms were measured with two assays, ELISA and TR-FIA.ResultssuPAR levels in healthy controls were significantly lower than those who had glomerular diseases but were not significantly different between FSGS patients and glomerular controls. Intact suPAR (I-II-III) levels were noted to be elevated in glomerular diseases including FSGS. uPAR fragment (I) levels measured with the TR-FIA 4 assay were significantly higher in FSGS (695.4 + 91.29 pMol/L) than glomerular controls (239.1 + 40.45 pMol/L, P = 0.001). However, suPAR(I) levels were not significantly different between recurrent FSGS and nonrecurrent FSGS patients.ConclusionOur analysis of suPAR using the ELISA assay used in all previous studies does not appear to be a useful marker for FSGS nor serve as a predictor for its recurrence after transplantation. The TR-FIA assay results suggest that uPAR(I) is a potential biomarker for FSGS but not of its recurrence.© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

32 keywords...

hide…